The Role of Apoptosis in Tissue Homeostasis, Malignancies, and Disease Pathogenesis

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Autophagy".

Deadline for manuscript submissions: closed (10 March 2025) | Viewed by 7157

Special Issue Editors


E-Mail Website
Guest Editor
Department of Morphology, Surgery & Experimental Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy
Interests: cancers; immunology; flow cytometry; apoptosis; cell cycle; MDM2 inhibitors; TRAIL

E-Mail Website
Guest Editor
Department of Environmental and Prevention Sciences and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy
Interests: cancer; nanodelivery; MDM2 inhibitors; p53; TRAIL
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Environmental and Prevention Sciences and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy
Interests: cancer; p53; inflammation; oxidative stress; neurodegenerative disorders

Special Issue Information

Dear Colleagues,

Apoptosis is a hallmark physiological process that normally occurs during the cell life in response to a wide variety of stimuli and conditions necessary during the tissue development, remodeling, and homeostasis. Apoptotic cells undergo morphological alteration, leading to the formation of apoptotic bodies which are cleared by scavenger cells.

Intrinsic and extrinsic stresses may induce apoptosis. Intrinsic stresses such as oncogene expression, DNA damage, hypoxia and metabolic deprivation may trigger the p53 pathway with caspase activation and the release of apoptogenic factors from damaged mitochondria. Extrinsic stresses activate members of the TNF family including Fas, Fas-L, and TRAIL receptors systems, and can be also driven by insults from cytotoxic drugs, radiation and pro-apoptotic granzymes.

In this context, autophagy is a fundamental process that guarantees the regeneration of cells which have undergone stress or poor nutrient conditions. Therefore, the crosstalk between autophagy and apoptosis also influences cell fate.

Apoptotic pathways are widely are often found to be missing or altered in neoplastic cells. The mutation of the p53 pathway and the lack of caspase activity are the major modifications found in human malignancies. Further evidence suggests p53-dependent apoptosis in neurodegenerative diseases such as Parkinson’s, Alzheimer’s, Huntington’s, and amyotrophic lateral sclerosis disease and during the cell death of the neural and vascular cells of the retina in diabetic retinopathy. Apoptosis is also a hallmark checkpoint for the development of autoimmunity, where the dysregulated elimination of cells may also contribute to systemic autoimmune diseases e.g., multiple sclerosis, systemic lupus erythematosus, and psoriasis.

This Special Issue aims to provide a platform for the collection of original research and review articles that investigate the role of apoptosis in health and disease. The final goal is to increase our knowledge of the apoptotic process and to improve available therapeutic options to overcome disease progression.

Research areas may include (but are not limited to) preclinical investigations into cell death molecular mechanisms, aspects of cell biology during the apoptotic process, and apoptosis induction after pharmacological treatments including drug delivery systems, in addition to clinical investigations into oncological, neurodegenerative and autoimmune diseases.

Dr. Fabio Casciano
Dr. Rebecca Voltan
Dr. Arianna Romani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • apoptosis
  • cell death
  • p53 pathway
  • autophagy
  • caspase
  • mitochondria
  • neurodegeneration
  • inflammation
  • drug discovery
  • cancer
  • targeted anticancer therapy
  • autoimmunity
  • nanodelivery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 4247 KiB  
Article
Enhanced Anti-Melanoma Activity of Nutlin-3a Delivered via Ethosomes: Targeting p53-Mediated Apoptosis in HT144 Cells
by Arianna Romani, Giada Lodi, Fabio Casciano, Arianna Gonelli, Paola Secchiero, Giorgio Zauli, Olga Bortolini, Giuseppe Valacchi, Daniele Ragno, Agnese Bondi, Mascia Benedusi, Elisabetta Esposito and Rebecca Voltan
Cells 2024, 13(20), 1678; https://doi.org/10.3390/cells13201678 - 11 Oct 2024
Cited by 1 | Viewed by 1581
Abstract
This study evaluated ethosomes as a novel nanodelivery system for nutlin-3a, a known MDM2 inhibitor and activator of the p53 pathway, to improve nutlin-3a’s poor solubility, limiting its bio-distribution and therapeutic efficacy. The potential of nutlin-3a-loaded ethosomes was investigated on two in vitro [...] Read more.
This study evaluated ethosomes as a novel nanodelivery system for nutlin-3a, a known MDM2 inhibitor and activator of the p53 pathway, to improve nutlin-3a’s poor solubility, limiting its bio-distribution and therapeutic efficacy. The potential of nutlin-3a-loaded ethosomes was investigated on two in vitro models of melanoma: the HT144 cell line p53wild-type and the SK-MEL-28 cell line p53mutated. Nutlin-3a-loaded ethosomes were characterized for their physicochemical properties and used to treat melanoma cells at different concentrations, considering nutlin-3a solution and empty ethosomes as controls. The biological effects on cells were evaluated 24 and 48 h after treatment by analyzing the cell morphology and viability, cell cycle, and apoptosis rate using flow cytometry and the p53 pathway’s activation via Western blotting. The results indicate that ethosomes are delivery systems able to maintain nutlin-3a’s functionality and specific biological action, as evidenced by the molecular activation of the p53 pathway and the biological events leading to cell cycle block and apoptosis in p53wild-type cells. Nutlin-3a-loaded ethosomes induced morphological changes in the HT144 cell line, with evident apoptotic cells and a reduction in the number of viable cells of over 80%. Furthermore, nutlin-3a-loaded ethosomes successfully modulated two p53-regulated proteins involved in survival/apoptosis, with up to a 2.5-fold increase in membrane TRAIL-R2 and up to an 8.2-fold decrease in Notch-1 (Notch intracellular domain, NICD) protein expression. The expression of these molecules is known to be altered or dysfunctional in a large percentage of melanoma tumors. Notably, ethosomes, regardless of their nutlin-3a loading, exhibited the ability to reduce HT144 melanoma cellular migration, as assessed in real time using xCELLigence, likely due to the modification of lipid rafts, suggesting their potential antimetastatic properties. Overall, nutlin-3a delivery using ethosomes appears to be a significantly effective means for upregulating the p53 pathway and downregulating active Notch-1, while also taking advantage of their unexpected ability to reduce cellular migration. The findings of this study could pave the way for the development of specific nutlin-3a-loaded ethosome-based medicinal products for cutaneous use. Full article
Show Figures

Graphical abstract

Review

Jump to: Research

22 pages, 1936 KiB  
Review
Hedgehog and PI3K/Akt/mTOR Signaling Pathways Involvement in Leukemic Malignancies: Crosstalk and Role in Cell Death
by Mariaconcetta Sicurella, Marica De Chiara and Luca Maria Neri
Cells 2025, 14(4), 269; https://doi.org/10.3390/cells14040269 - 13 Feb 2025
Viewed by 976
Abstract
The Hedgehog (Hh) and PI3K/Akt/mTOR signaling pathways play a pivotal role in driving the initiation and progression of various cancers, including hematologic malignancies such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). These [...] Read more.
The Hedgehog (Hh) and PI3K/Akt/mTOR signaling pathways play a pivotal role in driving the initiation and progression of various cancers, including hematologic malignancies such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). These pathways are often dysregulated in leukemia cells, leading to increased cell growth, survival, and drug resistance while also impairing mechanisms of cell death. In leukemia, the Hh pathway can be abnormally activated by genetic mutations. Additionally, the PI3K/Akt/mTOR pathway is frequently overactive due to genetic changes. A key aspect of these pathways is their interaction: activation of the PI3K/Akt pathway can trigger a non-canonical activation of the Hh pathway, which further promotes leukemia cell growth and survival. Targeted inhibitors of these pathways, such as Gli inhibitors and PI3K/mTOR inhibitors, have shown promise in preclinical and clinical studies. Full article
Show Figures

Figure 1

40 pages, 4523 KiB  
Review
Apoptosis, a Metabolic “Head-to-Head” between Tumor and T Cells: Implications for Immunotherapy
by Ornella Franzese, Pietro Ancona, Nicoletta Bianchi and Gianluca Aguiari
Cells 2024, 13(11), 924; https://doi.org/10.3390/cells13110924 - 27 May 2024
Cited by 2 | Viewed by 3762
Abstract
Induction of apoptosis represents a promising therapeutic approach to drive tumor cells to death. However, this poses challenges due to the intricate nature of cancer biology and the mechanisms employed by cancer cells to survive and escape immune surveillance. Furthermore, molecules released from [...] Read more.
Induction of apoptosis represents a promising therapeutic approach to drive tumor cells to death. However, this poses challenges due to the intricate nature of cancer biology and the mechanisms employed by cancer cells to survive and escape immune surveillance. Furthermore, molecules released from apoptotic cells and phagocytes in the tumor microenvironment (TME) can facilitate cancer progression and immune evasion. Apoptosis is also a pivotal mechanism in modulating the strength and duration of anti-tumor T-cell responses. Combined strategies including molecular targeting of apoptosis, promoting immunogenic cell death, modulating immunosuppressive cells, and affecting energy pathways can potentially overcome resistance and enhance therapeutic outcomes. Thus, an effective approach for targeting apoptosis within the TME should delicately balance the selective induction of apoptosis in tumor cells, while safeguarding survival, metabolic changes, and functionality of T cells targeting crucial molecular pathways involved in T-cell apoptosis regulation. Enhancing the persistence and effectiveness of T cells may bolster a more resilient and enduring anti-tumor immune response, ultimately advancing therapeutic outcomes in cancer treatment. This review delves into the pivotal topics of this multifaceted issue and suggests drugs and druggable targets for possible combined therapies. Full article
Show Figures

Figure 1

Back to TopTop